Vaxart VXRT stock analysis!!

Vaxart released a study on April 22 indicating that almost 19 million more American adults would get COVID-19 vaccines if they could do so via a pill rather than a shot. "Needle injections present a barrier to getting people vaccinated, and we have a solution that we believe will be effective and would allow people to avoid injections they don't want to have," Vaxart CEO Andrei Floroiu said in a press release. A phase 1 study showed Vaxart's oral tablet COVID-19 vaccine candidate induced T-cell responses in patients, which the company believes could protect against new coronavirus strains. Vaxart's vaccine was also found to be generally well-tolerated. Investors appear to be eagerly awaiting upcoming presentations by Vaxart's management team. Today the company will host a webinar on the importance of T-cell responses for COVID-19 and share new comparative data for its vaccine candidate. Vaxart founder and chief scientific officer Sean Tucker will also give a presentation next week at the World Vaccine Congress Washington regarding the benefits of its oral vaccine. Additionally, Vaxart has become increasingly popular among traders on #Reddit and other social media platforms in recent weeks. This is no doubt amplifying the moves in its stock price, which is likely to remain volatile.